Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lebrikizumab in adolescents with moderate-to-severe atopic dermatitis
NCT04250350Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2020
- Primary completion
- Apr 2022
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 3, open-label, single-arm trial of lebrikizumab in atopic dermatitis (AD), sponsored by Eli Lilly and Company. Primary endpoint: Percentage of Participants Discontinued From Study Treatment Due to Adverse Events (AEs) at Week 52. Started Feb 2020; status: completed.
02
Drugs
lebrikizumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT04250350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04250350.